Fountain Healthcare Partners
VC Fund
Dublin, Ireland
Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.
- Total investments:
- 50
- Last investment:
- Lead investor:
- 42%
- Fund size:
- $128M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Fountain Healthcare Partners invests in
Stages Fountain Healthcare Partners invests in
Countries Fountain Healthcare Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $6.3M–$43M
- Series B
- $5.5M–$68M
- Series C
- $3.3M–$110M
Investment Focus
Industry
- Health Care 21 (42%)
- Biotechnology 19 (38%)
- Medical 12 (24%)
- Medical Device 8 (16%)
- Therapeutics 7 (14%)
Stage
- Series A 16 (32%)
- Series B 14 (28%)
- Series C 7 (14%)
- Series D 2 (4%)
- Post-IPO Equity 2 (4%)
Country
- Ireland 12 (24%)
- United States 5 (10%)
- France 3 (6%)
- Belgium 2 (4%)
- United Kingdom 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Aidan King
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 8 | Find email | |
Ena Prosser
Partner
|
Partner | Total investments: 7 | Find email | |
Justin Lynch
Partner & CFO
|
Partner & CFO | Total investments: 7 | Find email | |
Manus Rogan
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 14 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Neurent Medical
|
Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $74.5M / Series C / Feb 11, 2026 | |
Exciva
|
exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M / Series B / Jan 20, 2026 | |
XyloCor Therapeutics
|
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively. | $67.5M / Series B / Jan 07, 2025 | |
Mainstay Medical
|
Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $125M / Private Equity / Feb 26, 2024 | |
MMI
|
We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $110M / Series C / Feb 21, 2024 | |
Corteria Pharmaceuticals
|
Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure. | $69.5M / Series A / Sep 07, 2023 | |
Dualyx
|
Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases. | $43.5M / Series A / May 15, 2023 | |
Neuromod Devices
|
Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'. | $16.6M / Series B / Apr 13, 2023 | |
|
MMI
|
We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $75M / Series B / Jul 20, 2022 | |
Ermium Therapeutics
|
Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company isbased in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education. | $6.3M / Series A / Jun 30, 2022 | |
| See all 50 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Fountain Healthcare Partners invest in?
Fountain Healthcare Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 50 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Fountain Healthcare Partners's check size?
Fountain Healthcare Partners typically joins rounds of $6.3M–$43M at Series A, $5.5M–$68M at Series B and $3.3M–$110M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fountain Healthcare Partners participates in.
How do I contact Fountain Healthcare Partners?
Public channels for Fountain Healthcare Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fountain Healthcare Partners?
The team at Fountain Healthcare Partners includes Aidan King (Co-Founder & Managing Partner), Ena Prosser (Partner) and Justin Lynch (Partner & CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
